TY  - JOUR
AU  - Püllen, Lukas
AU  - Radtke, Jan P
AU  - Wiesenfarth, Manuel
AU  - Roobol, Monique J
AU  - Verbeek, Jan F M
AU  - Wetter, Axel
AU  - Guberina, Nika
AU  - Pandey, Abhishek
AU  - Hüttenbrink, Clemens
AU  - Tschirdewahn, Stephan
AU  - Pahernik, Sascha
AU  - Hadaschik, Boris A
AU  - Distler, Florian A
TI  - External validation of novel MRI-based models for prostate cancer prediction.
JO  - BJU international
VL  - 125
IS  - 3
SN  - 1464-4096
CY  - Oxford
PB  - Wiley-Blackwell39962
M1  - DKFZ-2019-02710
SP  - 407-416
PY  - 2020
N1  - 2020 Mar;125(3):407-416
AB  - To validate three novel risk models (RM) combining mpMRI and clinical parameters to predict significant prostate cancer (sPC) through an external cohort, including the recently updated European Randomised Study of Screening for PC (ERSPC) risk-calculator.We retrospectively analyzed 307 men who underwent mpMRI prior to transperineal ultrasound fusion biopsy between 10/2015 and 07/2018 at two German centers. mpMRI was rated by PI-RADSv2.0 and sPC was defined as ISUP Gleason grade group ≥2.The prediction performance of the three models (MRI-ERSPC-3/4, RM by Radtke et al. and RM by Distler et al.) were compared using ROC-curve-analyses with area under the curve (AUC), calibration curve analyses and decision curves to assess net-benefit.ROC-AUCs of the three novel models (MRI-ERSPC-3/4; Radtke's RM and Distler's RM were 0.82; 0.85 and 0.83, respectively). Calibration curve analyses showed the best intercept for MRI-ERSPC-3 and -4 of 0.35 and 0.76. Net benefit analyses indicated clear benefit of MRI-ERSPC-3/4-RM compared to the other two validated models. The MRI-ERSPC-RC-3/4 demonstrated a discrimination benefit for a risk threshold of up to 15
LB  - PUB:(DE-HGF)16
C6  - pmid:31758738
DO  - DOI:10.1111/bju.14958
UR  - https://inrepo02.dkfz.de/record/147733
ER  -